LRIG1 Antibody (B-2): sc-514577

LRIG1 Antibody (B-2) is a mouse monoclonal IgM antibody that detects LRIG1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-LRIG1 antibody (B-2) is available as the non-conjugated form. LRIG1, also known as leucine-rich repeats and immunoglobulin-like domains protein 1, plays a crucial role in cellular signaling by interacting with the epidermal growth factor receptor family of receptor tyrosine kinases. LRIG1 (B-2) antibody recognizes a protein that acts as a negative feedback regulator, enhancing ubiquitination of these receptors and promoting their degradation, which helps control cell proliferation and prevent excessive signaling that can lead to tumorigenesis. LRIG1 exists as a single-pass type I membrane protein characterized by an ectodomain containing 15 leucine-rich repeats, which can be cleaved into N-terminal and C-terminal fragments, influencing regulatory functions. LRIG1 expression appears in all human glioma cell lines with localization to perinuclear compartments, cytoplasmic compartments, and cell surface, highlighting a role in maintaining cellular homeostasis and potential tumor suppression through downregulation of EGF and related proteins including ErbB-2, ErbB-3, and ErbB-4, which promote cancer cell growth, migration, and invasion.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LRIG1 Antibody (B-2) References:

1. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?  |  Hedman, H., et al. 2002. Acta Oncol. 41: 352-4. PMID: 12234026
2. LRIG1 protein in human cells and tissues.  |  Nilsson, J., et al. 2003. Cell Tissue Res. 312: 65-71. PMID: 12684867
3. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.  |  Thomasson, M., et al. 2003. Br J Cancer. 89: 1285-9. PMID: 14520461
4. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.  |  Laederich, MB., et al. 2004. J Biol Chem. 279: 47050-6. PMID: 15345710
5. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases.  |  Tanemura, A., et al. 2005. Dermatol Surg. 31: 423-30. PMID: 15871317
6. Increased copy number at 3p14 in breast cancer.  |  Ljuslinder, I., et al. 2005. Breast Cancer Res. 7: R719-27. PMID: 16168117
7. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.  |  Guo, D., et al. 2006. Acta Neuropathol. 111: 238-46. PMID: 16532360
8. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.  |  Goldoni, S., et al. 2007. Oncogene. 26: 368-81. PMID: 16847455
9. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.  |  Yang, WM., et al. 2006. BJU Int. 98: 898-902. PMID: 16978290
10. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.  |  Ji, Y., et al. 2022. Semin Cancer Biol. 82: 120-133. PMID: 33476721
11. Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.  |  Umeh-Garcia, M., et al. 2022. Br J Cancer. 127: 436-448. PMID: 35440669
12. LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses.  |  Ta, HM., et al. 2024. Sci Immunol. 9: eadi7418. PMID: 38758807

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LRIG1 Antibody (B-2) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-LRIG1 Antibody (B-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LRIG1 Antibody (B-2) Specifications

Alternate Product Name: LRIG1

Product Clone Name: B-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 727-757

Epitope Target: LRIG1

Epitope Species: human

Product Reactivity/Detection: LRIG1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for LRIG1 Antibody (B-2): P: Blocking Peptide